2-(溴甲基)-5-氟吡啶氢溴酸 | 954225-35-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(溴甲基)-5-氟吡啶氢溴酸
• 中文别名: 2-(溴甲基)-5-氟吡啶
• 英文名称: 2-(bromomethyl)-5-fluoropyridine
• CAS: 954225-35-5
• 化学式: C₆H₅BrFN
• mdl: MFCD09027050
• 分子量: 190.015
• InChiKey: LTRPARICWZBDRI-UHFFFAOYSA-N

物化性质

• 沸点：
  193℃
• 密度：
  1.632
• 闪点：
  71℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-(溴甲基)-5-氟吡啶氢溴酸 在 三溴化磷 、 potassium carbonate 、 caesium carbonate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 1-[2-(4-bromomethyl-2-methyl-phenyl)-2-oxo-ethyl]-4-(5-fluoro-pyridin-2-ylmethoxy)-1H-pyridin-2-one
  参考文献：
  名称：

  Design, synthesis and evaluation of MCH receptor 1 antagonists—Part III: Discovery of pre-clinical development candidate BI 186908

  摘要：

  Although overweight and obesity are highly prevalent conditions, options to treat them are still very limited. As part of our search for safe and effective MCH-R1 antagonists for the treatment of obesity, two series of pyridones and pyridazinones were evaluated. Optimization was aimed at improving DMPK properties by increasing metabolic stability and improving the safety profile by reducing inhibition of the hERG channel and reducing the potential to induce phospholipidosis. Steric shielding of a labile keto moiety with an ortho-methyl group and fine-tuning of the polarity in several parts of the molecule resulted in BI 186908 (11g), a potent and selective MCH-R1 antagonist with favorable DMPK and CMC properties. Chronic administration of BI 186908 resulted in significant body weight reduction comparable to sibutramine in a 4 week diet-induced obesity model in rats. Based on its favorable safety profile, BI 186908 was advanced to pre-clinical development. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.05.065
• 作为产物：
  描述：

  2‐methyl‐5‐fluoropyridine 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 四氯化碳 为溶剂， 反应 2.0h， 以50%的产率得到2-(溴甲基)-5-氟吡啶氢溴酸
  参考文献：
  名称：

  6-Arylmethylidene Penicillin-Based Sulfone Inhibitors for Repurposing Antibiotic Efficiency in Priority Pathogens

  摘要：

  The ability of 6-(aryl)methylidene penicillin-based sulfones 1-7 to repurpose beta-lactam antibiotics activity with bacterial species that carry carbapenem-hydrolyzing class D beta-lactamases (OXA-23, OXA-24/40 and OXA-48), as well as with class A (TEM-1, CTX-M-2) and class C (CMY-2, DHA-1) enzymes, is reported. The combinations imipenem/3 and imipenem/4 restored almost completely the antibiotic efficacy in OXA-23 and OXA-24/40 carbapenemase-producing A. baumannii strains (1 mu g mL(-1)) and also provided good results for OXA-48 carbapenemase-producing K. pneumoniae strains (4 mu g mL(-1)). Compounds 2-6 in combinations with ceftazidime and ampicillin were also efficient in restoring antibiotic efficacy in E. coli strains carrying class C (CMY-2 and DHA-1) and class A (TEM-1 and CTX-M-2) beta-lactamase enzymes, respectively. Kinetic and inhibition studies with the OXA-24/40 enzyme, protein mass spectrometry analysis and docking studies allowed us to gain an insight into the inhibition mechanism and the experimentally observed differences between the ligands.

  DOI：

  10.1021/acs.jmedchem.0c00127

文献信息

• [EN] NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS<br/>[FR] NOUVEAUX COMPOSÉS DE TÉTRAZOLE ET LEUR UTILISATION DANS LE TRAITEMENT DE LA TUBERCULOSE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019034729A1

  公开（公告）日：2019-02-21

  The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.

  这项发明涉及到式（I）的化合物或其药用盐以及它们在治疗中的应用，例如在治疗分枝杆菌感染或治疗由分枝杆菌引起的疾病，如结核病。
• [EN] SPIROCYCLIC COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS<br/>[FR] COMPOSÉS SPIROCYCLIQUES EN TANT QUE MODULATEURS DE CANAUX SODIQUES DÉPENDANTS DU VOLTAGE
  申请人：LUPIN LTD

  公开号：WO2012049555A1

  公开（公告）日：2012-04-19

  The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions modulated by VGSCs. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions by modulators of VGSC of Formula (I).

  本发明涉及式(I)化合物及其制备方法，这些化合物可用于治疗、预防和管理由电压门控钠通道(VGSCs)调节的疾病、障碍、综合征或状况。本发明还涉及通过式(I)的VGSC调节剂治疗、预防、管理和/或减轻这些疾病、障碍、综合征或状况的方法。
• [EN] INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA PROTÉINE KINASE I INTERAGISSANT AVEC LE RÉCEPTEUR POUR LE TRAITEMENT D'UNE MALADIE
  申请人：UNIV TEXAS

  公开号：WO2021046515A1

  公开（公告）日：2021-03-11

  Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1 -mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

  本文披露了一些抑制RIPK1的化合物、药物组合物和治疗RIPK1介导疾病的方法，如神经退行性疾病、炎症性疾病和癌症。
• AZINONE-SUBSTITUTED AZEPINO[b]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF
  申请人：Guzzo Peter R.

  公开号：US20110003793A1

  公开（公告）日：2011-01-06

  Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.

  揭示了新型MCH-1受体拮抗剂。这些化合物用于治疗各种疾病，包括肥胖、焦虑、抑郁、非酒精性脂肪肝病和精神疾病。本发明还描述了制备这些化合物的方法。
• [EN] BENZIMIDAZOLE DERIVATIVES AND THEIR USES<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE ET LEURS UTILISATIONS
  申请人：AMGEN INC

  公开号：WO2020210597A1

  公开（公告）日：2020-10-15

  The present invention provides compounds which inhibit the activity of TRPC6, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

  本发明提供了抑制TRPC6活性的化合物，其药学上可接受的盐，包括本发明化合物的药物组合物，制造本发明化合物的方法以及其治疗用途。